Blood can be a scarce resource, but a multitude of approaches are promising new ways to store, create, and deliver blood’s component parts to patients in need. Click here to read the article in its entirety. Author, Leah Shaffer, science writer, for Proceedings of the...
Nivesh Mittal, PhD, Product Development Scientist, to propel production of ErythroMer™ March 24, 2020, Baltimore, Md. – KaloCyte, Inc., a preclinical-stage healthcare biotechnology company developing ErythroMer, a synthetic, bio-inspired red blood cell...
As KaloCyte has re-established itself in Maryland, Elaine E. Haynes, President and CEO, said they are moving closer to bringing their artificial blood cell product, ErythroMer, to clinical trials and are eyeing a Series A funding round later this year. Read the...
The Capital M Podcast #LifeScienceRevolution: Proximity to Resources with KaloCyte. Listen to part 3 of the Capital M podcast, #LifeScienceRevolution: Proximity to Resources with KaloCyte. In this episode, Marty discusses business in Maryland with Elaine E. Hayne,...
KaloCyte CEO to Present at NIH Innovation Conference and Life Sciences Summit Company Continues Momentum Following Recent Relocation to Baltimore BALTIMORE, Md., November 4, 2019 – KaloCyte, Inc., a preclinical-stage healthcare biotechnology company developing a...
University of Maryland Medicine Bulletin Fall 2019 – Vol.104 – Number 2 Bold New Vision on Blood Research By: Christiana McCausland Each year there are perhaps as many as 20,000 preventable deaths caused by blood loss in the United States. In the U.S....
